SCHEMBL3492382

SCHEMBL3492382

COc1cccc(Cc2nc3sc(C(=O)O)c(C)c3c(=O)[nH]2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.59
ALDH1A1 P00352 6/20 0.59
KDM4E B2RXH2 1/20 0.59
MAPT P10636 6/20 0.55
MEN1 O00255 6/20 0.51
TDP1 Q9NUW8 3/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
PDE5A O76074 1/20 0.51
GAA P10253 1/20 0.51
KDM4C Q9H3R0 1/20 0.51
POLB P06746 3/20 0.50
CCNB2 O95067 1/20 0.50
CCNE2 O96020 1/20 0.50
CDK1 P06493 1/20 0.50
CDK4 P11802 1/20 0.50
CCNB1 P14635 1/20 0.50
CCND1 P24385 1/20 0.50
CCNE1 P24864 1/20 0.50
CDK2 P24941 1/20 0.50
CCNB3 Q8WWL7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494331 0.90 ALDH1A1 (0.57) KMT2AALDH1A1KDM4EMAPTMEN1
SCHEMBL3490870 0.90 KMT2A (0.55) KMT2AALDH1A1KDM4EMAPTMEN1
SCHEMBL4506239 0.89 KMT2A (0.63) KMT2AALDH1A1KDM4EMAPTMEN1
SCHEMBL3494144 0.88 MAPT (0.63) KMT2AALDH1A1KDM4EMAPTMEN1
SCHEMBL3491916 0.87 ALDH1A1 (0.61) KMT2AALDH1A1KDM4EMAPTMEN1
SCHEMBL3494432 0.87 KMT2A (0.60) KMT2AALDH1A1KDM4EMAPTMEN1
SCHEMBL13341339 0.86 ALDH1A1 (0.75) KMT2AALDH1A1KDM4EMAPTMEN1
SCHEMBL3493088 0.86 POLB (0.64) KMT2AALDH1A1KDM4EMAPTMEN1
SCHEMBL3492352 0.86 PDE5A (0.69) KMT2AALDH1A1KDM4EMAPTMEN1
SCHEMBL3493275 0.86 ALDH1A1 (0.60) KMT2AALDH1A1KDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870656-B2 Methods for treatment of heart failure CARDURION PHARMACEUTICALS, LLC (US) 2020-12-22 US disclosed
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE CARDURION PHARMACEUTICALS LLC (US) 2019-07-11 US disclosed
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD KMT2A 2820/4885ALDH1A1 762/4885KDM4E 4291/4885
US-10870656-B2 Methods for treatment of heart failure TNNT2, TNNI3, TNNC1 KMT2A 3654/4885ALDH1A1 748/4885KDM4E 3591/4885
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 KMT2A 2650/4885ALDH1A1 2303/4885KDM4E 2859/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 KMT2A 2650/4885ALDH1A1 2303/4885KDM4E 2859/4885
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE TNNT2, TNNI3, TNNC1 KMT2A 3654/4885ALDH1A1 748/4885KDM4E 3591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.